LOS ANGELES, May 23, 2019 /PRNewswire/ -- Wedbush Securities
is pleased to announce that Senior Vice President of Equity
Research, Laura Chico, Ph.D.,
initiates coverage on six stocks in the Healthcare and BioTech
space. Initiations are on the following: Acer Therapeutics Inc.
(ACER), Acorda Therapeutics, Inc. (ACOR), Alexion Pharmaceuticals
(ALXN), Biogen Inc (BIIB), Dova Pharmaceuticals, Inc. (DOVA), and
Sage Therapeutics, Inc. (SAGE).
Laura joined Wedbush in April and brings her nearly two decades
of industry and academia experience to her coverage and states,
"I'm happy to begin contributing to Wedbush's high-quality research
platform. This marks an exciting time in the biotech sector as many
small- and mid-cap companies are driving innovation, particularly
in the orphan disease and CNS space."
David Nierengarten, Ph.D.,
Managing Director and Head of Healthcare Equity Research adds,
"Laura's launch brings significant breadth to our biotechnology
research team, adding new therapeutic areas under coverage, as we
continue to expand our Healthcare research offering."
About Wedbush Securities
Since our founding in 1955,
Wedbush has been a leader in the financial industry providing our
clients with a wide range of services; including institutional
sales, correspondent clearing services, equity research, corporate
and municipal finance, equity market making, fixed income trading,
prime brokerage, and wealth management. Headquartered in
Los Angeles, with 100 registered
offices, the firm focuses on dedicated service, client financial
safety, continuity, and advanced technology.
Follow us on Twitter @Wedbush.
View original content to download
SOURCE Wedbush Securities